Dr. Daniel Watkins is a Co-Founder and serves as Chief Executive Officer at Mercury Data Science. He is also a Co-Founder and serves as Managing Director and Member of the Investment Team at Mercury Fund. He also serves as Board Observer at Ripple Science. He serves as Board Member at Resonant Therapeutics and Sinopsys Surgical. He focuses on startups utilizing software, cloud computing, and/or machine learning to drive the next wave of scientific innovation in healthcare, agriculture, and other industrial markets. Dan currently serves on the boards of Mercury portfolio companies Benson Hill, Clean Chemistry, Deep Imaging, DNAtrix, Resonant, Sinopsys, and Swift Biosciences. Dan's previous investments at Mercury have included Cgate Health (acq. by SCI Solutions). Prior to co-founding Mercury, Dan served in a number of operational roles including CEO of DNAtrix and Nanospectra Biosciences, both startup oncology companies. Previously, Dan was Vice President at a boutique investment banking firm and Worldwide Manager of Operations and Control Systems for Scientific Software-Intercomp (Baker Hughes). Dan received his B.S. from Rice University and his M.S. and Ph.D. from Carnegie Mellon University, all in Materials Science. Dan is also a co-founder of the Rice Alliance for Technology and Entrepreneurship at Rice University. Outside of Mercury, Dan serves on the advisory boards of Northwestern University's Innovation and New Ventures Office (INVO), the Rice Alliance, the University of Michigan's Venture Center Council, and the University of Illinois Proof of Concept Fund Committee.